KR20240167844A - 질소 함유 헤테로시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용 - Google Patents
질소 함유 헤테로시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용 Download PDFInfo
- Publication number
- KR20240167844A KR20240167844A KR1020247034812A KR20247034812A KR20240167844A KR 20240167844 A KR20240167844 A KR 20240167844A KR 1020247034812 A KR1020247034812 A KR 1020247034812A KR 20247034812 A KR20247034812 A KR 20247034812A KR 20240167844 A KR20240167844 A KR 20240167844A
- Authority
- KR
- South Korea
- Prior art keywords
- heterocyclyl
- alkyl
- cycloalkyl
- cancer
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210330007 | 2022-03-28 | ||
| CN202210330007.4 | 2022-03-28 | ||
| CN202210944231 | 2022-08-05 | ||
| CN202210944231.2 | 2022-08-05 | ||
| CN202211255163.5 | 2022-10-13 | ||
| CN202211255163 | 2022-10-13 | ||
| PCT/CN2023/084265 WO2023185793A1 (zh) | 2022-03-28 | 2023-03-28 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240167844A true KR20240167844A (ko) | 2024-11-28 |
Family
ID=88199144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247034812A Pending KR20240167844A (ko) | 2022-03-28 | 2023-03-28 | 질소 함유 헤테로시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250206760A1 (https=) |
| EP (1) | EP4501925A4 (https=) |
| JP (1) | JP2025509995A (https=) |
| KR (1) | KR20240167844A (https=) |
| CN (1) | CN118715216A (https=) |
| AU (1) | AU2023243776A1 (https=) |
| CA (1) | CA3253847A1 (https=) |
| MX (1) | MX2024011705A (https=) |
| TW (1) | TW202345816A (https=) |
| WO (1) | WO2023185793A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN121969632A (zh) * | 2023-09-27 | 2026-05-01 | 江苏恒瑞医药股份有限公司 | 一种喹唑啉衍生物的可药用盐、其结晶形式及用途 |
| CN121969633A (zh) * | 2023-09-27 | 2026-05-01 | 江苏恒瑞医药股份有限公司 | 一种喹唑啉衍生物的结晶形式及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1292591B1 (en) * | 2000-06-22 | 2005-02-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| DK1660090T3 (da) * | 2003-08-14 | 2012-12-17 | Array Biopharma Inc | Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer |
| ATE446294T1 (de) * | 2005-11-15 | 2009-11-15 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| AR092289A1 (es) * | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
| CN104744446B (zh) * | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| WO2017148391A1 (zh) | 2016-03-01 | 2017-09-08 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| TWI858848B (zh) * | 2018-05-08 | 2024-10-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | ＥｒｂＢ受體抑制劑 |
| EP4523755A3 (en) * | 2018-09-18 | 2025-06-11 | F. Hoffmann-La Roche AG | Quinazoline derivatives as antitumor agents |
| EP4100409B1 (en) | 2020-02-03 | 2024-08-28 | Boehringer Ingelheim International GmbH | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors |
| JP7626774B2 (ja) | 2020-02-03 | 2025-02-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
| WO2021179274A1 (en) * | 2020-03-13 | 2021-09-16 | Suzhou Zanrong Pharma Ltd. | ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| WO2021231400A1 (en) | 2020-05-12 | 2021-11-18 | Accutar Biotechnology, Inc. | Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors |
| TW202214654A (zh) | 2020-06-10 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合喹唑啉類衍生物、其製備方法及其在醫藥上的應用 |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| US20240398805A1 (en) * | 2021-02-05 | 2024-12-05 | Accutar Biotechnology Inc. | Quinazoline derived compounds as egfr inhibitors and their uses thereof |
| WO2023154124A1 (en) * | 2022-02-09 | 2023-08-17 | Enliven Therapeutics, Inc. | Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 |
-
2023
- 2023-03-28 CN CN202380022951.6A patent/CN118715216A/zh active Pending
- 2023-03-28 AU AU2023243776A patent/AU2023243776A1/en active Pending
- 2023-03-28 US US18/851,679 patent/US20250206760A1/en active Pending
- 2023-03-28 JP JP2024556197A patent/JP2025509995A/ja active Pending
- 2023-03-28 KR KR1020247034812A patent/KR20240167844A/ko active Pending
- 2023-03-28 EP EP23778158.8A patent/EP4501925A4/en active Pending
- 2023-03-28 WO PCT/CN2023/084265 patent/WO2023185793A1/zh not_active Ceased
- 2023-03-28 CA CA3253847A patent/CA3253847A1/en active Pending
- 2023-03-28 TW TW112111777A patent/TW202345816A/zh unknown
-
2024
- 2024-09-24 MX MX2024011705A patent/MX2024011705A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023243776A1 (en) | 2024-09-12 |
| US20250206760A1 (en) | 2025-06-26 |
| JP2025509995A (ja) | 2025-04-11 |
| CN118715216A (zh) | 2024-09-27 |
| EP4501925A4 (en) | 2025-08-27 |
| CA3253847A1 (en) | 2025-07-04 |
| EP4501925A1 (en) | 2025-02-05 |
| MX2024011705A (es) | 2024-11-08 |
| WO2023185793A1 (zh) | 2023-10-05 |
| TW202345816A (zh) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202325298A (zh) | 含氮的四環化合物、其製備方法及其在醫藥上的應用 | |
| CN113980032B (zh) | 稠合四环类衍生物、其制备方法及其在医药上的应用 | |
| TW202322819A (zh) | 含氮的四環化合物、其製備方法及其在醫藥上的應用 | |
| KR20240167844A (ko) | 질소 함유 헤테로시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용 | |
| CN116199703A (zh) | 稠合四环杂环化合物、其制备方法及其在医药上的应用 | |
| EP3556761B1 (en) | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | |
| TW202321263A (zh) | 磺醯胺衍生物、其製備方法及其在醫藥上的應用 | |
| KR20150108389A (ko) | 치환된 피롤로피리미딘 화합물, 이의 조성물 및 이에 의한 치료 방법 | |
| TWI845819B (zh) | 用作激酶抑制劑的化合物及其應用 | |
| JP2022554385A (ja) | Ｗｄｒ５阻害剤及び調節剤 | |
| CN118339157A (zh) | 氢化吲哚类化合物、其制备方法及其在医药上的应用 | |
| CN120535536A (zh) | 稠合杂芳基类化合物、其制备方法及其在医药上的应用 | |
| CN112996783A (zh) | 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2024539922A (ja) | ピリジル含有化合物 | |
| TW202246260A (zh) | 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用 | |
| AU2024319888A1 (en) | Heteroaryl compound, preparation method therefor, and use thereof in medicine | |
| CN117903172A (zh) | 取代的含氮杂芳基类化合物、其制备方法及其在医药上的应用 | |
| CN119855817A (zh) | 杂环炔基取代的酰胺衍生物、其制备方法及其应用 | |
| IL320545A (en) | Fused bicyclic compound | |
| CN117813288A (zh) | 芳氨基衍生物雌激素受体调节剂及其用途 | |
| EP4310081A1 (en) | Ctla-4 small molecule degradation agent and application thereof | |
| EA052991B1 (ru) | Азотсодержащее гетероциклическое соединение, способ его получения и его фармацевтическое применение | |
| JP2019509996A (ja) | コルチスタチン類縁体 | |
| CN117586265A (zh) | 含氮杂环类化合物、其制备方法及其在医药上的应用 | |
| CN119161325A (zh) | 内酰胺类化合物、其制备方法及其在医药上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |